All
CAR-T Cell Therapies Offer ‘An Opportunity for Majority of Patients’ With Lymphoma to Be Treated
March 14th 2022Unlike stem cell transplant, which has strict eligibility criteria, the majority of patients with blood cancer may be able to receive CAR-T cell therapy, regardless of other comorbidities, explained an expert.
FDA Approves Lynparza for Treatment of Certain Patients With High-Risk, Early-Stage Breast Cancer
March 11th 2022The FDA’s decision to OK Lynparza is based on data from the OlympiA trial, which showed that Lynparza reduced the risk of invasive breast cancer recurrences, second cancers or death by 42% versus placebo after initial treatment with chemotherapy.
Combination Maintenance Therapy After Stem Cell Transplant May Prolong Survival in Multiple Myeloma
March 9th 2022Maintenance therapy with Ninlaro and Revlimid in patients with recently diagnosed multiple myeloma who underwent a stem cell transplant may safely improve survival, although more research is needed especially in high-risk patients.
Novel Monoclonal Antibody Injection May Address Significant Unmet Need in Patients With Rare Tumor
March 7th 2022As surgery is the current standard of care for patients with tenosynovial giant cell tumor, the potential to add another treatment option with fewer complications may dramatically help patients with this rare tumor.
FDA Approves Opdivo-Chemotherapy Regimen for Pre-Surgical Treatment of Non-Small Cell Lung Cancer
March 5th 2022The FDA’s approval of the Opdivo plus platinum-doublet chemotherapy regimen marks the agency’s first greenlight, according to manufacturer Bristol Myers Squibb, of an immunotherapy-based treatment in the pre-surgical setting for non-small cell lung cancer.